What Did the Research Discover? Researchers investigated whether low-dose aspirin could reduce the risk of developing type 2 diabetes in older adults. The study included 16,209 people aged 70 and older (or 65 and older for some U.S. minority groups) who were generally healthy and did not have diabetes at the start of the study. Participants were randomly assigned to...
What Did the Research Discover? Researchers studied whether benzodiazepine use is linked to a higher risk of dementia or cognitive decline in older adults. The study followed 3,434 participants aged 65 and older in Seattle, Washington, who did not have dementia at the beginning of the study. They were observed for an average of 7.3 years, with cognitive tests given...
What did the research discover? Researchers tested a new treatment for depression called Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT). This treatment uses intermittent theta-burst stimulation (iTBS), a type of brain stimulation already approved by the U.S. Food and Drug Administration (FDA) for treatment-resistant depression. SAINT was designed...
What did the research discover? Researchers tested if a voice-activated therapy using cognitive behavioral therapy for insomnia (CBT-I) could help breast cancer survivors who have trouble sleeping. CBT-I is a type of talk therapy that teaches ways to improve sleep by changing habits and thoughts that make it hard to rest. This therapy was delivered through a smart...
For Immediate Release: March 20, 2025 Today, under the leadership of U.S. Department of Health and Human Services Secretary Robert F. Kennedy, Jr., the U.S. Food and Drug Administration unveiled the Chemical Contaminants Transparency Tool (CCT Tool), an online searchable database providing a consolidated list of contaminant levels (e.g., tolerances, action levels,...
For Immediate Release: March 21, 2025 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: On Thursday, the FDA approved Fabhalta (iptacopan) for the treatment of adults with complement 3 glomerulopathy (C3G) to reduce proteinuria. C3G is a rare disease that causes inflammation and damage to the kidney...